With a focus on controlling appetite and enhancing energy expenditure, it may provide a valuable solution for those struggling with obesity or metabolic syndrome
Tirzepatide: The First GLP-1/GIP Dual Agonist Tirzepatide is a dual incretin agonist that activates both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors and was developed to enhance metabolic and weight-loss outcomes beyond those achieved with GLP-1 receptor agonists alone
So much for beating the biological clock, as promised by a multimillion-dollar industry that promoted its technologies in part as a way for women to avoid detrimental career disruptions
Smoking status and nicotine dependence are partially assessed using self-reported questionnaires, which may introduce reporting bias and affect measurement accuracy
Specifically, where necessary, we converted data into a consistent format to ensure appropriate statistical comparisons
People discontinue medication for many reasons such as cost, insurance denials, shortages, plateaus, or side effects
